France's BioAlliance Pharma says it's full steam ahead for its strategy to acquire complementary products for oncology and HIV, despite Immtech's decision to end a trial for pafuramidine--a program BioAlliance is partnered on. Immtech announced late Friday that it is shelving a safety study of pafuramidine after seeing reports of liver and kidney abnormalities. The drug was being tested for pneumonia in HIV patients and for African sleeping sickness.
- here's the release
- read the AFX report